Clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies

Trial Profile

Clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2018

At a glance

  • Drugs Treosulfan (Primary)
  • Indications Acute myeloid leukaemia; Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Sponsors Medac
  • Most Recent Events

    • 26 Mar 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2019.
    • 01 Dec 2017 Results assessing efficacy and safety of treosulfan-based conditioning therapy [Ovastat] prior to allogeneic haematopoietic stem cell transplantation in paediatric patients, were published in the British Journal of Haematology.
    • 11 Jul 2017 This trial has been completed in Austria.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top